Treatment of microbial infections with compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase
Methods of inhibiting phagolysosomal fusion in patients infected with a microorganism involve the administration of a 4-hydroxyphenylpyruvate dioxygenase (HPPD)-inhibiting compound, such as 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) to the patient. A HPPD-inhibiting compound administered in an amount effective to enhance phagolysosomal fusion in the macrophages or neutrophils of the patient reduces or treats the infection. Methods for treating bacterial infections by administering a HPPD-inhibiting compound and reducing the production of pyomelanin or melanin in microorganisms are disclosed.
1. A method for treating a patient suffering from a bacterial infection, the method comprising administering a composition comprising 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) to the patient, the inhibitor being administered in an amount effective to treat the infection.
2. The method of claim 1 , wherein the amount of NTBC administered is effective to reduce bacterial pyomelanin production.
3. The method of claim 1 , wherein treating the infection comprises enhancing phagolysosomal fusion in the patient compared with a similarly infected patient not having been administered the inhibitor.
4. The method of claim 1 , wherein the NTBC is administered in a regime in combination with an antibacterial agent.
5. The method of claim 1 , wherein the infection is selected from a lung infection, an intestinal infection, cholera, pneumonia, septicemia, a urinary tract infection, a gastrointestinal infection, a skin infection and a soft tissue infection.
6. The method of claim 1 , wherein the composition is administered orally.
7. The method of claim 1 , wherein the bacterium is selected from Bordetella parapertussis, Borrelia burgdorferi, Corynebacterium diphtheriae, Enterococcus faecalis, Escherichia coli, Haemophilus influenzae, Legionella pneumophila, Listeria monocytogenes, Mycoplasma pneumoniae, Pseudomonas aeruginosa, Salmonella typhi, Salmonella typhimurium, Streptococcus agalactiae, Streptococcus pneumoniae, Vibrio cholerae, Yersinia pestis, and Burkholderia cenocepaci.
8. The method of claim 1 , wherein the amount of NTBC administered is from 0.1 mg/Kg to 10 mg/Kg.
9. The method of claim 4 , wherein the antibacterial agent is an antibiotic.
10. The method of claim 1 , wherein the bacterium has a blood titer in the patient and wherein the blood titer of the bacterium is reduced following administration of the NTBC.